Charles River Laboratories International (CRL) Stock Price
Charles River Laboratories International Price
Charles River Laboratories International (CRL) Stock | ISIN US1598641074 | WKN 939391. The current Charles River Laboratories International stock price is 184 USD (2026). Revenue is 4.06 B USD. Net income is 552.66 M USD. The P/E ratio is 16.5. Market capitalization is 9.12 B USD. Charles River Laboratories International operates in the Health sector.
Over the last 19 years Charles River Laboratories International grew revenue by 7.3% annually, reaching 4.02 B USD. Earnings per share have declined at 13.2% per year over the last 17 years. For Charles River Laboratories International, the net margin of -3.6% is down versus 11% a few years ago.
Charles River Laboratories International stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Charles River Laboratories International over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Charles River Laboratories International stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Charles River Laboratories International's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Charles River Laboratories International Price |
|---|
Charles River Laboratories International Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (B USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|
| 4.05 | 4.02 | 4.06 | 4.19 | 4.37 | 4.62 | 4.82 | 5.25 |
| -1.94 | -0.84 | 1 | 3.26 | 4.28 | 5.91 | 4.15 | 8.99 |
| 34.75 | 34.97 | 34.62 | 33.53 | 32.16 | 30.36 | 29.15 | 26.75 |
| 1.41 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 |
| 10 | -144 | 552 | 602 | 657 | 714 | 795 | 920 |
| -97.89 | -1,540 | -483.33 | 9.06 | 9.14 | 8.68 | 11.34 | 15.72 |
| 51.63 | 49.56 | 49.56 | 49.56 | 49.56 | 49.56 | 49.56 | 49.56 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Charles River Laboratories International generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Charles River Laboratories International retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Charles River Laboratories International's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Charles River Laboratories International has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Charles River Laboratories International's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Charles River Laboratories International stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International business model & stock analysis
Charles River Laboratories International SWOT Analysis
Strengths
Charles River Laboratories International Inc has established itself as a prominent player in the research and development services industry.
Strong financial performance and consistent revenue growth provide a solid foundation for future expansion and investment.
The company possesses a wide range of capabilities and expertise, offering a comprehensive suite of services to its clients.
Strong reputation and long-standing relationships with key industry partners contribute to a highly trusted brand image.
Weaknesses
Charles River Laboratories International Inc may face potential challenges in integrating newly acquired companies and maintaining consistent quality standards across all operations.
Reliance on a few major clients for a significant portion of revenue could pose a risk to the company's financial stability in case of client attrition.
Limited geographical presence may hinder the company's ability to tap into emerging markets and expand its client base.
The company might face regulatory constraints and compliance issues in the highly regulated industries it serves, increasing operational complexity.
Opportunities
Increasing demand for outsourcing in the pharmaceutical and biotechnology sectors opens up new growth opportunities for Charles River Laboratories International Inc.
Expansion into untapped markets, such as Asia and Latin America, could lead to additional revenue streams and diversification.
Advances in technology and innovation present the opportunity for the company to enhance its services and offer cutting-edge solutions to clients.
Strategic partnerships and collaborations with academic institutions and research organizations can foster innovation and strengthen the company's position in the market.
Threats
Intense competition from other contract research organizations may lead to pricing pressures and reduced market share.
Evolving regulatory landscape and potential changes in government policies could impact the company's operations and profitability.
Economic downturns and fluctuations in research and development budgets of pharmaceutical companies could affect demand for Charles River Laboratories International Inc's services.
Increasing scrutiny on animal testing practices may result in stricter regulations and a potential shift towards alternative testing methods.
Charles River Laboratories International Segments
Charles River Laboratories International Revenue by Segment (1/4)
3 Years
5 Years
Max
Details
Charles River Laboratories International Revenue by Segment (2/4)
Max
Details
Charles River Laboratories International Revenue by Segment (3/4)
3 Years
5 Years
10 Years
Max
Details
Charles River Laboratories International Revenue by Segment (4/4)
3 Years
5 Years
10 Years
Max
Details
Charles River Laboratories International Revenue by Region
3 Years
5 Years
Max
Details
Charles River Laboratories International Eulerpool Fair Value
Charles River Laboratories International historical P/E ratio, EBIT multiple, and P/S ratio
Charles River Laboratories International annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Charles River Laboratories International shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Charles River Laboratories International Earnings Estimates
Charles River Laboratories International Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/7/2026 | 1.96USD | 987.53 MUSD | 2026 Q1 |
| 2/18/2026 | 2.37USD | 996.87 MUSD | 2025 Q4 |
| 11/6/2024 | 3.03USD | 1.09 BUSD | 2024 Q3 |
| 5/9/2024 | 2.53USD | 1.03 BUSD | 2024 Q1 |
| 2/20/2024 | 2.43USD | 997.2 MUSD | 2023 Q4 |
| 8/1/2023 | 2.88USD | 1.05 BUSD | 2023 Q2 |
| 5/2/2023 | 2.63USD | 982.73 MUSD | 2023 Q1 |
| 2/14/2023 | 2.77USD | 1.05 BUSD | 2022 Q4 |
| 11/2/2022 | 2.52USD | 984.99 MUSD | 2022 Q3 |
| 8/3/2022 | 2.76USD | 1.01 BUSD | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Charles River Laboratories International stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Charles River Laboratories International shareholder structure
| % | Name |
|---|---|
11.85399% | |
5.80541% | |
4.0263% | |
3.77631% | |
3.58197% | |
3.5292% | |
3.38473% | |
3.12508% | |
2.90982% | |
2.88066% |
Charles River Laboratories International Executives and Management Board
Mr. James Foster
(74)Chairman of the Board, President, Chief Executive Officer · since 1976
Ms. Birgit Girshick
(55)Chief Operating Officer, Corporate Executive Vice President
Mr. Joseph LaPlume
(51)Corporate Executive Vice President - Corporate Development and Strategy
Ms. Victoria Creamer
(55)Corporate Executive Vice President, Chief People Officer
Ms. Reshema Kemps-Polanco
(52)Independent Director
Charles River Laboratories International Supply Chain
Frequently asked questions about Charles River Laboratories International
The business model of Charles River Laboratories International Inc primarily revolves around providing research and development (R&D) solutions and services to the pharmaceutical, biotechnology, and medical device companies. As a leading contract research organization (CRO), the company offers a wide range of preclinical and clinical laboratory services, including safety assessment, discovery support, manufacturing support, and laboratory animal research services. Charles River Laboratories operates on a fee-for-service basis, collaborating with its clients to accelerate drug discovery, development, and commercialization processes. With a focus on quality, reliability, and scientific expertise, the company aims to support its clients in advancing their scientific research and achieving their business goals.
Charles River Laboratories International stock
Charles River Laboratories International Peer Group
Charles River Laboratories International Ticker
Charles River Laboratories International FIGI
All fundamentals and in-depth analysis of Charles River Laboratories International
Our stock analysis for Charles River Laboratories International Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Charles River Laboratories International Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.